[4].
In a literature review, Iwanaga et al. noticed that VZV reactivation
following the COVID-19 vaccines has been reported all over the world and
with different vaccine types a few months after COVID-19
commercialization.[5]
The VZV reactivation prevention relies on cell-mediated immunity.
Decreasing cell-mediated immunity is associated with a decline in
VZV-specific T cells, disrupting immune control and rising the risk of
reactivation [6]. In addition, a decline in major
class1-histocompatibility complex results in the inhibition of
interferon response serves as an antiviral, hence triggering the viral
replication [1]. This immune system downregulation is
affected by age as the major risk factor for 90% of cases of shingle[6]. In addition to the immunosenescence, trauma,
malignancy, chronic kidney and liver disease, HIV infection, and
immunosuppressive therapy predispose to the virus reactivation